Bank of Montreal Can Decreases Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Bank of Montreal Can cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 21.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,502 shares of the company’s stock after selling 13,004 shares during the period. Bank of Montreal Can’s holdings in Takeda Pharmaceutical were worth $619,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Rise Advisors LLC bought a new stake in Takeda Pharmaceutical during the first quarter valued at $26,000. GAMMA Investing LLC lifted its position in shares of Takeda Pharmaceutical by 50.9% during the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after acquiring an additional 966 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares during the period. Headlands Technologies LLC acquired a new position in Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Finally, Blue Trust Inc. lifted its stake in Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after acquiring an additional 2,330 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Down 0.3 %

Takeda Pharmaceutical stock opened at $14.29 on Wednesday. The firm has a market cap of $45.47 billion, a PE ratio of 25.98, a P/E/G ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. The firm’s 50 day moving average price is $14.53 and its two-hundred day moving average price is $13.75.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The firm had revenue of $7.75 billion during the quarter. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.